RJFSA
PBYI icon

Raymond James Financial Services Advisors’s Puma Biotechnology PBYI Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,030
Closed -$88K – 2740
2019
Q4 		$88K Sell
10,030
-62
-0.6% -$513 ﹤0.01% 2715
2019
Q3 		$109K Buy
+10,092
New +$109K ﹤0.01% 2619

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Raymond James Financial Services Advisors's PBYI Position: Q1 2020 in Review

Raymond James Financial Services Advisors sold out of Puma Biotechnology (PBYI) in Q1 2020, closing a stake of 10,030 shares — an estimated $88K sold.

Raymond James Financial Services Advisors first reported a position in PBYI in Q3 2019 and held it in 2 quarters. The position peaked at $109K in Q3 2019. 125 funds tracked by Wall St. Rank hold PBYI as of Q1 2020.

  • Raymond James Financial Services Advisors reported no remaining Puma Biotechnology position as of Q1 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,030 Puma Biotechnology shares in Q1 2020, an estimated $88K.
  • Raymond James Financial Services Advisors first reported a position in Puma Biotechnology in Q3 2019 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Puma Biotechnology position peaked at $109K in Q3 2019.
  • 125 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2020, filed 21 Apr 2020.